Megakaryocytes play a central role in the biology of myeloproliferative neoplasms (MPNs), yet their in vivo proteomic characterization remains a major challenge due to low abundance and disrupted tissue architecture. This webinar introduces a novel low-input spatial proteomics workflow that enables, for the first time, direct molecular analysis of these rare cells within their native bone marrow environment.
Why is megakaryocyte proteomics in MPNs challenging?
Megakaryocytes are rare, spatially distributed cells embedded in a highly complex and often fibrotic bone marrow environment. Traditional approaches rely on in vitro differentiation or bulk tissue analysis—losing critical spatial and disease specific context.
Key limitations include:
- Low cell abundance in tissue samples
- Disrupted bone marrow architecture in MPNs
- Inadequate sensitivity of conventional proteomic workflows
This creates a major barrier to understanding how these cells drive disease progression.
What new biological insights were uncovered?
This approach revealed, for the first time, that megakaryocytes in MPNs exhibit distinct proteomic signatures across disease subtypes.
Key findings include:
- Identification of 4,875 proteins across patient cohorts
- Clear proteomic separation between MPN subtypes
- Differential pathway regulation:
- Primary myelofibrosis: ECM organization, RNA metabolism
- Essential thrombocythemia: platelet activation pathways
- Polycythemia vera: altered metabolic processes
- Discovery of novel biomarkers, including senescence-associated proteins
These insights provide a more precise understanding of disease mechanisms at the cellular level.
What does this enable for your research?
This workflow enables researchers to:
- Generate molecular data from rare cell population
- Preserve spatial and pathological context in analysis
- Identify clinically relevant biomarkers and therapeutic targets
- Reduce experimental iteration through robust, reproducible workflows
Ultimately, it supports faster and more confident translation from biological insight to clinical relevance.
